Form 4: Spyre Therapeutics CEO Sells Shares
Insider Transaction (Form 4)
Cameron Turtle, Chief Executive Officer and a Director of Spyre Therapeutics, Inc., sold 15,000 shares of common stock on October 1, 2026.
Summary
- Open-market sale: disposed of 600 Common Stock at $89.14 ($53,484) on October 1, 2026; holds 551,940 after (Direct).
- Open-market sale: disposed of 2,683 Common Stock at $90.10 ($241,738) on October 1, 2026; holds 549,257 after (Direct).
- Open-market sale: disposed of 2,638 Common Stock at $91.49 ($241,351) on October 1, 2026; holds 546,619 after (Direct).
- Open-market sale: disposed of 3,989 Common Stock at $92.31 ($368,225) on October 1, 2026; holds 542,630 after (Direct).
- Open-market sale: disposed of 4,990 Common Stock at $93.37 ($465,916) on October 1, 2026; holds 537,640 after (Direct).
- Open-market sale: disposed of 100 Common Stock at $93.91 ($9,391) on October 1, 2026; holds 537,540 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $1,380,105 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Cameron Turtle — Director, Officer (Chief Executive Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-01 | Open-market sale | Common Stock | 600 | $89 | $53.5K | 551,940 |
| 2026-10-01 | Open-market sale | Common Stock | 2,683 | $90 | $241.7K | 549,257 |
| 2026-10-01 | Open-market sale | Common Stock | 2,638 | $91 | $241.4K | 546,619 |
| 2026-10-01 | Open-market sale | Common Stock | 3,989 | $92 | $368.2K | 542,630 |
| 2026-10-01 | Open-market sale | Common Stock | 4,990 | $93 | $465.9K | 537,640 |
| 2026-10-01 | Open-market sale | Common Stock | 100 | $94 | $9.4K | 537,540 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-01 | Open-market sale (600 shares) |
| 2026-10-01 | Open-market sale (2,683 shares) |
| 2026-10-01 | Open-market sale (2,638 shares) |
| 2026-10-01 | Open-market sale (3,989 shares) |
| 2026-10-01 | Open-market sale (4,990 shares) |
| 2026-10-01 | Open-market sale (100 shares) |
Keywords
insider transaction, Form 4, SYRE, Spyre Therapeutics, Inc., bearish, Cameron Turtle
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.